Goldstein Market Intelligence analyst forecast that anti-diabetic drugs market size is growing at a CAGR of 10.12% through the forecast years of 2019-2035. Type 2 diabetes and other non-communicable diseases are a major public health concern globally with 6.4% of the adult’s population i.e. 285 million people are suffering from diabetes, which is projected to reach the number 552 million by 2030, according to the International Diabetes Federation. In US alone approximating 79 million individuals are reported pre- diabetic.
We will be launching Diabetology Division to help needy patients for healthy life also we will provide affordable prices. We will be adding Both Type-1 & 2 brand therapy and the insulin’s we will be bringing the US.
Diabetology Products
| # | Product Name | Combination |
|---|---|---|
| 1 | Mrtformin 500mg (PR)&(SR), 1000mg (PR) & (SR) | Submet |
| 2 | Metformin 500mg (PR) & (SR)+ Glimipride 1mg | Submet-G1 |
| 3 | Metformin 1000mg (PR) & (SR)+ Glimipride 1mg | Submet-Plus G1 |
| 4 | Metformin 500mg (PR) & (SR)+ Glimipride 2mg | Submet-G2 |
| 5 | Metformin 1000mg (PR) & (SR)+ Glimipride 2mg | Submet-Plus G2 |
| 6 | Metformin 500mg (SR) & (XR) + Gliclazide 60mg | Submet-GL 60mg |
| 7 | Metformin 500mg (SR) & (XR)+ Gliclazide 80mg | Submet-GL 80mg |
| 8 | Metformin 500mg (SR) & (XR)+ Gliclazide 30mg | Submet-GL 30mg |
| 9 | Metformin 500mg (SR) & (XR) + Telenigliptine 20mg | Submet-T |
| 10 | Metformin 500mg + Glimepride 1mg+Pioglitazone 15mg | Piglicon-GM1 |
| 11 | Metformin 500mg + Glimepride 2mg+Pioglitazone 15mg | Piglicon-GM2 |
| # | Product Name | Combination |
|---|---|---|
| 1 | Vildagliptin 50mg, 100mg | Vilexa |
| 2 | Vildagliptin 50mg + Metformin 500mg | Vilexa-MET |
| 3 | Vildagliptin 100mg + Metformin 500mg | Vilexa-MET |
| 4 | Vildagliptin 50mg + Metformin 1000mg | Vilexa-MET |
